grant
Novel patient biomarkers and mechanisms of TKI associated Cardiotoxicity
Organization UT SOUTHWESTERN MEDICAL CENTERLocation DALLAS, UNITED STATESPosted 5 Aug 2023Deadline 30 Apr 2028
NIHUS FederalResearch GrantFY202521+ years old3-10CAMCF-IAddressAdultAdult HumanAffectAgammaglobulinaemia tyrosine kinaseAgeAmericanAnimal ModelAnimal Models and Related StudiesAnimalsAortaArrhythmiaAtrialAtrial FibrillationAuricular FibrillationAutomobile DrivingB cell differentiation factorB cell progenitor kinaseB cell stimulating factor 2B-Cell CLLB-Cell Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphogenous LeukemiaB-Cell Chronic Lymphoid LeukemiaB-Cell Differentiation FactorB-Cell Differentiation Factor-2B-Cell Lymphocytic LeukemiaB-Cell Stimulatory Factor-2B-Lymphocytic LeukemiaBCDFBSF-2BSF2BloodBlood PressureBlood Reticuloendothelial SystemBlood VesselsBlood monocyteBruton's tyrosine kinaseCTLA-8CTLA-8 GeneCTLA8CTLA8 GeneCXCL8CancersCardiacCardiac ArrhythmiaCardiac AtriumCardiac Muscle CellsCardiac MyocytesCardiac ToxicityCardiocyteCardiotoxicCardiotoxicityCardiovascularCardiovascular Body SystemCardiovascular Organ SystemCardiovascular systemCell BodyCellsChronic B-Lymphocytic LeukemiaChronic Lymphatic LeukemiaChronic Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaChronic Lymphogenous LeukemiaClinicalCytotoxic T-Lymphocyte-Associated Antigen 8Cytotoxic T-Lymphocyte-Associated Antigen 8 GeneCytotoxic T-Lymphocyte-Associated Serine Esterase 8Cytotoxic T-Lymphocyte-Associated Serine Esterase 8 GeneDataDevelopmentDrugsECGEFRACEKGEjection FractionElectrocardiogramElectrocardiographyEventExpectancyFibrosisGCP1GenderHPGFHeart ArrhythmiasHeart AtriumHeart Muscle CellsHeart VascularHeart myocyteHematologic CancerHematologic MalignanciesHematologic NeoplasmsHematological MalignanciesHematological NeoplasmsHematological TumorHematopoietic CancerHepatocyte-Stimulating FactorHolter ElectrocardiographyHolter MonitoringHoltmonHumanHybridoma Growth FactorHypertensionIFN-beta 2IFNB2IL-1IL-17IL-17 GeneIL-17AIL-17A GeneIL-6IL-8IL1IL17IL17 ProteinIL17 geneIL17AIL17A GeneIL6 ProteinIL8IL8 geneImmuneImmune Cell ActivationImmune responseImmunesImmunogenomicsImmunologic TechnicsImmunologic TechniquesImmunological TechnicsImmunological TechniquesIncidenceInflammationInflammation MediatorsInflammatoryInnate Immune ResponseInterleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8)Interleukin 17 (Cytotoxic T-Lymphocyte-Associated Serine Esterase 8) GeneInterleukin 17 PrecursorInterleukin 17 Precursor GeneInterleukin IInterleukin-1Interleukin-17Interleukin-6InterventionK60LeadLeftLinkLymphocyte-Stimulating HormoneMGI-2Macrophage Cell FactorMalignant Hematologic NeoplasmMalignant NeoplasmsMalignant TumorMarrow monocyteMeasuresMediatingMediatorMedicationMethodsModelingModern ManMonitorMyeloid Differentiation-Inducing ProteinOhioOncologyOncology CancerOralOral AdministrationOral Drug AdministrationPTK InhibitorsPathway interactionsPatientsPb elementPharmaceutical PreparationsPhenotypePlasmacytoma Growth FactorPlayPopulationPreclinical dataPrediction of Response to TherapyPredisposing FactorProspective StudiesProtein Tyrosine Kinase InhibitorsResearch ResourcesResourcesRiskRisk FactorsRoleSCYB8T Helper FactorTK InhibitorsTSG-1TechniquesTestingTherapeutically TargetableTimeToxic effectToxicitiesTyrosine Kinase InhibitorUpregulationVascular Hypertensive DiseaseVascular Hypertensive DisorderVentricularadulthoodagesanimal datab-ENAPbpk proteinbtk proteincardiac MRIcardiac imagingcardiac magnetic resonance imagingcardiac scanningcardiomyocytecardiovascular effectschronic lymphoid leukemiacirculatory systemcohortdevelopmentaldrivingdrug/agenteffective therapyeffective treatmentheart imagingheart scanningheavy metal Pbheavy metal leadhigh blood pressurehigh riskhost responsehyperpiesiahyperpiesishypertensive diseasehypertensive disorderimmune activationimmune system responseimmunoresponseimprovedimproved outcomeindexinginflammatory mediatorinhibitorinhibitor druginhibitor therapeuticinhibitor therapyinsightinterferon beta 2intraoral drug deliverykinase inhibitorlymphocyte activating factormalignancymodel of animalmonocytemortalitymouse modelmultidisciplinarymurine modelneoplasm/cancernoveloncology programpathwaypatient biomarkerspre-clinicalpre-clinical studypreclinicalpreclinical findingspreclinical informationpreclinical studypredict therapeutic responsepredict therapy responseprimary end pointprimary endpointprospectiveprospective testrecruitresponsesingle cell genomicssocial rolesuccesstherapy predictiontreatment predictiontreatment response predictionvascular
Description preview
ABSTRACT:
Nearly 250,000 adults are affected by chronic lymphocytic leukemia (CLL). Bruton’s Tyrosine kinase inhibitors
(BTKIs) dramatically improve survival in CLL. However, up to 38% of patients develop atrial fibrillation (AF) and
other cardiovascular toxicities. Ibrutinib is the first BTKI approved which has these toxicities but our data…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click